Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Derek C Angus, Tom van der Poll
New England Journal of Medicine, Volume 369, Issue 9, Page 840-851, August 2013.
August 29, 2013: New England Journal of Medicine
#2
REVIEW
Valery L Feigin, Mohammad H Forouzanfar, Rita Krishnamurthi, George A Mensah, Myles Connor, Derrick A Bennett, Andrew E Moran, Ralph L Sacco, Laurie Anderson, Thomas Truelsen, Martin O'Donnell, Narayanaswamy Venketasubramanian, Suzanne Barker-Collo, Carlene M M Lawes, Wenzhi Wang, Yukito Shinohara, Emma Witt, Majid Ezzati, Mohsen Naghavi, Christopher Murray
BACKGROUND: Although stroke is the second leading cause of death worldwide, no comprehensive and comparable assessment of incidence, prevalence, mortality, disability, and epidemiological trends has been estimated for most regions. We used data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) to estimate the global and regional burden of stroke during 1990-2010. METHODS: We searched Medline, Embase, LILACS, Scopus, PubMed, Science Direct, Global Health Database, the WHO library, and WHO regional databases from 1990 to 2012 to identify relevant studies published between 1990 and 2010...
January 18, 2014: Lancet
#3
JOURNAL ARTICLE
Thomas A Golper, Rachel Fissell, William H Fissell, P Matthew Hartle, M Lee Sanders, Gerald Schulman
No abstract text is available yet for this article.
January 2014: American Journal of Kidney Diseases
#4
REVIEW
Gearoid M McMahon, Sushrut S Waikar
No abstract text is available yet for this article.
July 2013: American Journal of Kidney Diseases
#5
REVIEW
Andrew Davenport, Jawad Ahmad, Ali Al-Khafaji, John A Kellum, Yuri S Genyk, Mitra K Nadim
Hepatorenal syndrome (HRS) is defined as the occurrence of renal dysfunction in a patient with end-stage liver cirrhosis in the absence of another identifiable cause of renal failure. The prognosis of HRS remains poor, with a median survival without liver transplantation of <6 months. However, understanding the pathogenesis of HRS has led to the introduction of treatments designed to increase renal perfusion and mean arterial blood pressure using vasopressors and albumin, which has led to improvement in renal function in ∼50% of patients...
January 2012: Nephrology, Dialysis, Transplantation
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
